Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 registration study assessing Monovalent Norovirus Vaccine Candidate

Next Previous
Trial Profile

Phase 3 registration study assessing Monovalent Norovirus Vaccine Candidate

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VXA G1.1 NN (Primary)
  • Indications Norovirus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Vaxart

Most Recent Events

  • 20 Mar 2025 According to a Vaxart media release, the trial is expected to begin as early as 2026.
  • 14 Mar 2024 According to a Vaxart media release, the company expects the Phase 2b study will generate sufficient safety data to have an End-of-Phase 2 meeting with the FDA. The End-of-Phase 2 meeting will allow the Company to gain concurrence on the scope and design of the Phase 3 pivotal efficacy study in adults over 18 years of age.
  • 11 Sep 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top